Latest Insider Transactions at Tcr2 Therapeutics Inc. (TCRR)
This section provides a real-time view of insider transactions for Tcr2 Therapeutics Inc. (TCRR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TCR2 THERAPEUTICS INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TCR2 THERAPEUTICS INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2022
|
Angela Justice Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,273
-3.28%
|
$2,273
$1.39 P/Share
|
|
Dec 02
2022
|
Garry E Menzel President and CEO |
SELL
Open market or private sale
|
Direct |
8,408
-3.8%
|
$8,408
$1.39 P/Share
|
|
Dec 02
2022
|
Peter Olagunju Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,273
-3.58%
|
$1,273
$1.39 P/Share
|
|
Dec 02
2022
|
Alfonso Quintas Cardama Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,636
-2.56%
|
$3,636
$1.39 P/Share
|
|
Dec 01
2022
|
Angela Justice Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,576
+46.24%
|
-
|
|
Dec 01
2022
|
Garry E Menzel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
221,058
+50.0%
|
-
|
|
Dec 01
2022
|
Peter Olagunju Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,409
+48.41%
|
-
|
|
Dec 01
2022
|
Alfonso Quintas Cardama Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
95,385
+40.13%
|
-
|
|
Jul 05
2022
|
Garry E Menzel President and CEO |
BUY
Bona fide gift
|
Indirect |
265,459
+42.21%
|
-
|
|
Jul 05
2022
|
Garry E Menzel President and CEO |
SELL
Bona fide gift
|
Direct |
180,932
-63.32%
|
-
|
|
Jul 05
2022
|
Garry E Menzel President and CEO |
SELL
Bona fide gift
|
Indirect |
84,527
-100.0%
|
-
|
|
Feb 28
2022
|
Angela Justice Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,236
+18.74%
|
$4,472
$2.3 P/Share
|
|
Feb 28
2022
|
Garry E Menzel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,425
+0.78%
|
$2,850
$2.3 P/Share
|
|
Dec 09
2021
|
Garry E Menzel President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
175,000
+49.36%
|
$0
$0.74 P/Share
|
|
Dec 09
2021
|
Alfonso Quintas Cardama Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
43,000
+47.82%
|
$0
$0.74 P/Share
|
|
Aug 31
2021
|
Angela Justice Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
379
+4.84%
|
$5,306
$14.26 P/Share
|
|
Aug 31
2021
|
Garry E Menzel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
422
+8.56%
|
$5,908
$14.26 P/Share
|
|
Aug 31
2021
|
Alfonso Quintas Cardama Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
164
+4.02%
|
$2,296
$14.26 P/Share
|
|
Apr 02
2021
|
Angela Justice Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,752
+48.82%
|
$94,528
$14.81 P/Share
|
|
Feb 28
2021
|
Angela Justice Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
326
+50.0%
|
$5,216
$16.12 P/Share
|
|
Feb 28
2021
|
Garry E Menzel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
686
+14.38%
|
$10,976
$16.12 P/Share
|
|
Feb 28
2021
|
Alfonso Quintas Cardama Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
708
+15.88%
|
$11,328
$16.12 P/Share
|
|
Dec 22
2020
|
Robert Hofmeister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+13.25%
|
$0
$0.74 P/Share
|
|
Dec 14
2020
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-57.59%
|
$70,000
$35.0 P/Share
|
|
Dec 14
2020
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+36.54%
|
$10,000
$5.88 P/Share
|
|
Nov 17
2020
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,666
-46.0%
|
$109,980
$30.0 P/Share
|
|
Nov 17
2020
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+28.02%
|
$10,000
$5.88 P/Share
|
|
Nov 12
2020
|
Robert Hofmeister Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-20.47%
|
$500,000
$25.1 P/Share
|
|
Nov 12
2020
|
Robert Hofmeister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.99%
|
$0
$0.74 P/Share
|
|
Oct 29
2020
|
Robert Hofmeister Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-33.98%
|
$380,000
$19.1 P/Share
|
|
Oct 29
2020
|
Robert Hofmeister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+25.36%
|
$0
$0.74 P/Share
|
|
Aug 31
2020
|
Garry E Menzel President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,132
+24.98%
|
$11,320
$10.1 P/Share
|
|
Aug 31
2020
|
Alfonso Quintas Cardama Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,118
+26.87%
|
$11,180
$10.1 P/Share
|
|
Feb 19
2019
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
706,666
+14.85%
|
$10,599,990
$15.0 P/Share
|
|
Feb 19
2019
|
Mpm Bio Ventures 2014, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,148,297
+28.57%
|
-
|
|
Feb 19
2019
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
666,667
+16.51%
|
$10,000,005
$15.0 P/Share
|
|
Feb 19
2019
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,704,315
+29.73%
|
-
|
|
Feb 19
2019
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
807,256
+50.0%
|
-
|